在反馈环节，专家组对生殖医学中心的各项工作给予充分的肯定，尤其在该科室精细化管理、医疗质量持 续改进方面给予高度评价。专家组认为，在生育意愿和出生率持续下降的大环境下，生殖医学中心门诊量 及辅助生殖助孕周期数依然逐步上升，实属难得。同时，专家组就检查中发现的问题，以及中心下一步的 学科建设和发展规划，提出了中肯的建设性指导意见。 经过4个多小时的严谨校验检查，专家组一致认为，烟台山医院生殖医学中心开展的相关技术在两年运行周 期内管理和伦理制度落实到位，技术实施与掌握成熟，自查机制运行严格，各项主要技术指标均完全达到 相关技术规范要求，无违法违规情况，严格落实了国家和我省关于人类辅助生殖技术的相关要求。经无记 名投票，生殖医学中心以961分的高分(满分1000分)全票再次通过辅助生殖技术校验。 烟台山医院党委副书记衣振中表示，本次校验既是对医院生殖医学中心两年来工作的一次全面检阅和把脉 问诊，更是帮助医院进一步提升技术、规范管理、保障安全的宝贵契机。烟台山医院将高度重视、虚心听 取、认真落实各位专家的指导意见，持续推动生殖医学专业的规范化、高质量发展。校验中专家组对医院 工作的认可，既是荣誉，更是责任。未来烟台 ...

该项目由国家中医药管理局、国家卫生健康委、中央军委后勤保障部联合发布，东部战区总医院生殖医学科携手南京中医药大学第二附属医院针灸科牵 头，聚焦"卵巢功能减退"诊疗瓶颈，构建标准化协作机制、智能化数据平台与规范化诊治方案，形成可借鉴、可扩展的中西医协同"江苏样板"。大会汇聚 国内生殖与中医药领域权威专家，共话前沿技术与临床需求对接，为从业者提供思想碰撞与资源对接的高端平台。 2026年1月24日，由江苏省发育生物学学会主办、东部战区总医院与江苏省第二中医院联合承办的"首届金陵生殖障碍中西医协作研讨会"在南京开幕。同 期，国家重大疑难疾病(卵巢功能减退)中西医临床协作项目(ZDYN-2024-A-0156)正式启动，标志着国家级中西医协同防治卵巢功能减退平台落地江苏。 东部战区总医院生殖医学科自建科以来深度融合中西医，形成"电针-艾灸-中药"三位一体、分证型精准干预路径——先调准节律，再疏通冲任，终补养卵 巢，实现调经-促排-助孕一体化。临床数据显示，该方案可提升卵巢储备、改善卵子质量，实现"卵巢保养"与青春续航双赢，为卵巢功能减退女性重启好 孕之门。 生殖医学科主任姚兵教授介绍，未来科室将以国家级项目为抓手，继 ...

Group 1 - The core viewpoint of the articles highlights that the company, Jinxin Reproductive Medicine (01951), has shown resilience in its IVF cycle numbers, with a projected improvement in Q4 2025 compared to Q3 2025, despite an 8.0% decline in H1 2025 compared to H1 2024 [1] - The overall decline in IVF cycles has narrowed from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025, indicating a recovery trend [1] - The flagship hospital in Chengdu has seen a turnaround, with IVF cycles growing by 1.3% in 2025 compared to a decline of -1.9% in the first three quarters of 2025 [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels, while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to strengthen its market position in Chengdu and expand its capacity in the Greater Bay Area following the relocation of new facilities, while also addressing overseas policy changes to tap into international market growth potential [2] - The company intends to leverage national fertility support policies and industry development opportunities to solidify its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]

Core Viewpoint - The introduction of advanced IVF technology in Urumqi aims to assist infertile families in realizing their dreams of parenthood through a collaborative medical aid initiative from Zhejiang University Women's Hospital [1][3]. Group 1: Medical Aid Initiative - The medical aid initiative began in September 2020, focusing on establishing a comprehensive reproductive technology system in Xinjiang, with experts from Zhejiang University Women's Hospital stationed at local hospitals [1][3]. - Over five years, a complete and independent assisted reproductive technology system was developed, providing hope to infertile families [3][10]. Group 2: Success Stories - A case study highlights a patient, referred to as Xiaomin, who underwent successful IVF treatment after losing her fallopian tubes, resulting in a healthy baby born in May 2024 [4][5]. - By the end of 2025, the reproductive medicine department at Xinjiang People's Hospital is expected to have completed over 500 cycles of assisted reproductive technology [5]. Group 3: Systematic Development - The initiative is led by prominent figures such as Academician Huang Hefeng, who emphasizes a systematic approach to building local medical capabilities through training and technology transfer [7][9]. - A "two-location integrated" treatment model was introduced, allowing patients from Akesu and surrounding areas to access advanced medical services in Urumqi [8][9]. Group 4: Training and Capacity Building - Local clinical and nursing teams are receiving hands-on training at Zhejiang University Women's Hospital, ensuring the sustainability of skills and knowledge transfer [9][10]. - The establishment of a remote consultation mechanism allows for real-time expert guidance, enhancing the quality of care provided to patients in Xinjiang [8][10].

Core Viewpoint - The article discusses the challenges and opportunities in reproductive health, emphasizing the importance of early childbearing and the declining quality of male sperm, while also highlighting the advancements in assisted reproductive technologies [4][5][6]. Group 1: Reproductive Health Challenges - The incidence of infertility in China has increased from 12% in 2007 to 18% in 2020, with male and female factors contributing equally to infertility [9]. - Women over 35 face significant declines in fertility due to reduced egg quantity and quality, while men also experience declining sperm quality with age [8][9]. - The societal trend of late marriage and childbearing is influenced by various factors, including career pressures and educational costs, leading to a rise in high-age pregnancies [9][10]. Group 2: Sperm Quality Decline - Data from the Central South University shows a significant decline in sperm quality, with the acceptance rate for donated sperm dropping from 45.9% in 2006 to around 20% currently [11][12]. - The World Health Organization has revised the normal reference values for sperm parameters, indicating a downward trend in male fertility [11][12]. - Factors such as lifestyle choices, including sleep patterns and stress, significantly impact sperm quality, with younger individuals showing better sperm parameters compared to older students [13][16]. Group 3: Assisted Reproductive Technologies - The Central South University reproductive center has frozen approximately 820,000 embryos, with many serving as a form of "fertility insurance" for couples [28]. - The center emphasizes the importance of sperm donation and the strict regulations surrounding it, including the anonymity of donors and the limitation on the number of births per donor [20][22]. - Advances in reproductive technology are shifting the focus from sperm donation to self-sperm storage and fertility preservation, reflecting a growing trend in the market [23][28].

Core Insights - The academic exchange focused on the role of growth hormone in regulating ovarian function and its clinical applications in reproductive medicine [1][3][5] Group 1: Expert Insights - Professor Xu Chunyang, a leading expert in reproductive medicine, emphasized the importance of growth hormone in directly affecting ovarian cells and indirectly stimulating the liver to secrete IGF-I, which is crucial for follicle development and embryo implantation [3][5] - The challenges of low ovarian response (POR) and decreased fertility in older women were highlighted as common issues in clinical practice [3][5] Group 2: Clinical Applications - Growth hormone usage should follow the principle of "individualized precision treatment," tailoring treatment plans based on patient age, ovarian reserve function, and specific conditions [5] - The application of growth hormone can enhance ovarian sensitivity to ovulation induction drugs, thereby increasing the yield of quality oocytes, but requires careful monitoring of dosage and timing [5][6] Group 3: Collaborative Learning - Active communication among medical staff regarding complex clinical cases was encouraged, with Professor Xu providing solutions to various challenges faced in practice [6][8] - The hospital aims to regularly conduct high-level academic activities to integrate cutting-edge reproductive medicine technologies with clinical practice, enhancing infertility treatment services [8]

Core Viewpoint - The article discusses a groundbreaking study that introduces an AI-based microfluidic sperm detection and recovery system, named STAR, which successfully enabled clinical pregnancy in a male diagnosed with azoospermia, marking a significant advancement in the treatment of male infertility [3][4][8]. Group 1: Technology and Methodology - The STAR system utilizes high-power imaging technology to scan semen samples from azoospermic males, capable of capturing and analyzing millions of images in under an hour [4]. - The system combines high-speed imaging, microfluidic chips, and deep learning algorithms, processing semen at a flow rate of 400μL per hour and capturing images at 300 frames per second [4]. - A time-consistency filter enhances reliability by confirming sperm detection only if at least three out of ten consecutive frames identify sperm [4]. Group 2: Clinical Application and Results - The STAR system was applied to a couple who had been trying to conceive for nearly 20 years, with the male having undergone multiple sperm retrieval attempts with no success [7]. - Initial manual searches of the male's semen sample showed no sperm, but the STAR system identified 7 sperm (2 active) from 2.5 million images scanned [8]. - The two active sperm were successfully injected into two mature eggs, resulting in a positive pregnancy after 19 years of attempts, demonstrating the potential of AI-guided microfluidic technology in overcoming long-standing barriers in male infertility [8]. Group 3: Implications and Future Research - This breakthrough signifies a potential shift from "no hope" to "hope for parenthood" for many couples facing male infertility challenges [8]. - The research team is planning larger clinical studies to evaluate the reproducibility and effectiveness of the STAR system across a broader patient population [8].

Core Insights - The article discusses the significant public health challenge of infertility, affecting 12.6%-17.5% of couples globally, and highlights the role of in vitro fertilization (IVF) as a primary assisted reproductive technology [3] - A recent study published in Nature Medicine introduces the concept of Oocyte and Early Embryo Competence Defects (OECD) and identifies six subtypes based on clinical characteristics, providing new diagnostic standards and genetic mapping for female infertility [4][7] Group 1: OECD Concept and Subtypes - The study systematically proposes the concept of OECD and categorizes it into six subtypes: Empty Follicle, Oocyte Maturation Arrest, Fertilization Failure, Zygote Arrest, Early Embryonic Arrest, and Mixed Phenotype, along with corresponding diagnostic criteria [4][7] - The research involved whole-exome sequencing of 2,140 female OECD infertility patients to explore the genetic landscape and subtype classification [7] Group 2: Genetic Findings and Implications - The research team identified 183 pathogenic or potentially pathogenic mutations across 28 known genes, with varying diagnostic rates among subtypes; for instance, the Empty Follicle subtype had a diagnostic rate of 53% [9] - The study also identified and validated two potential pathogenic genes, MLH3 and CENPH, and suggested nine previously unreported associated genes, providing biological insights into the potential pathogenic mechanisms of ovarian insufficiency [9] - Overall, the genetic findings explain 12.8%-23.1% of OECD cases, offering valuable information for developing diagnostic genetic screening and standardizing subtype classification for OECD patients [9]

Group 1 - The core viewpoint emphasizes the importance of accelerating and improving the reproductive support policy system to promote high-quality population development [1] - Various regions are progressively including suitable assisted reproductive technologies in medical insurance reimbursement as related policies are implemented [1] - A live discussion featuring experts from Peking University Third Hospital will take place on July 30, focusing on assisted reproductive technologies and their impact on patients and clinical practices [1] Group 2 - Dr. Li Rong, a prominent figure in reproductive medicine, serves as the Deputy Director of Peking University Third Hospital and has received the National Outstanding Youth Science Fund [5] - Dr. Liu Ping, a key contributor to the establishment of assisted reproductive technology in mainland China, is currently the Chief Physician at the Reproductive Medicine Center of Peking University Third Hospital [5] - Both experts hold significant positions in various medical associations related to reproductive health and medicine [5] Group 3 - The event can be accessed through the People's Good Doctor App, where users can find health-related content and live discussions [6] - Users are encouraged to follow the People's Health public WeChat account for additional health information and to download the app for viewing [7]

Core Insights - The increasing prevalence of infertility issues among families is attributed to the fast-paced lifestyle and environmental pressures, leading to a growing reliance on assisted reproductive technologies (ART) [1] - Significant advancements in ART, such as multi-gene screening and fertility preservation, have provided hope for many couples wishing to become parents, marking important progress in the field of reproductive health [1] Group 1: Development and Application of ART - Assisted reproductive technology has evolved from initial in vitro fertilization (IVF) to include breakthroughs like multi-gene screening and fertility preservation [1] - The upcoming live discussion on May 9 will feature experts discussing the development and application of ART, highlighting its role in achieving "优生优育" (optimal birth and nurturing) [1] Group 2: Expert Profiles - Huang Guoning, a leading figure in reproductive medicine, holds multiple prestigious positions, including Director of the Reproductive Medicine Center at Chongqing Maternal and Child Health Hospital and Chair of the Reproductive Medicine Branch of the Chinese Medical Association [5] - Lin Ge, another prominent expert, serves as the President of CITIC Xiyuan Reproductive and Genetic Specialty Hospital and has significant roles in various national committees related to reproductive health and stem cell research [5] Group 3: Viewing Information - The live discussion can be accessed through the People's Good Doctor App, which provides health education content [6] - Users can also follow the People's Health public WeChat account for additional health-related interactions and to download the app [7]